Department of Biochemistry, Indian Institute of Science, Bangalore 560012, India.
Department of Biochemistry, Indian Institute of Science, Bangalore 560012, India.
Int Immunopharmacol. 2021 Jun;95:107515. doi: 10.1016/j.intimp.2021.107515. Epub 2021 Mar 15.
Multiple steps of the retroviral infection process have been targeted over the years to develop therapeutic approaches, starting from the entry of the virus into the cell till the viral DNA integration to host genome. Inhibitors against the Human Immunodeficiency Virus (HIV) integrase is the newest among the therapies employed against HIV. Recombination activating gene 1 (RAG1) is an integral protein involved in the generation of diversity of antibodies and T-cell receptors and is one of the partners of the RAG complex. Studies have shown structural and functional similarities between the HIV integrase and RAG1. Recently, we and others have shown that some of the integrase inhibitors can interfere with RAG binding and cleavage, hindering its physiological functions. This mini review focuses on the HIV integrase, integrase inhibitors and their effect on RAG activities.
多年来,人们针对逆转录病毒感染过程的多个步骤进行了研究,以开发治疗方法,从病毒进入细胞到病毒 DNA 整合到宿主基因组。针对人类免疫缺陷病毒 (HIV) 整合酶的抑制剂是针对 HIV 采用的最新疗法之一。重组激活基因 1 (RAG1) 是一种参与抗体和 T 细胞受体多样性产生的整合蛋白,是 RAG 复合物的一个组成部分。研究表明,HIV 整合酶和 RAG1 之间存在结构和功能上的相似性。最近,我们和其他人已经表明,一些整合酶抑制剂可以干扰 RAG 的结合和切割,从而阻碍其生理功能。这篇迷你综述重点介绍 HIV 整合酶、整合酶抑制剂及其对 RAG 活性的影响。